The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Bayer UK launches new CanesMeno Educational Hub and product range to transform menopause support: Leverkusen Friday, January ...

2025--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple ...

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...

Despite challenges in the Crop Science division, the strength of the Pharmaceuticals division and steady performance in Consumer Health are encouraging. Moreover, Bayer recently scored an ...

Bayer Thai Co., Ltd. has been honoured with the 2025 Thailand Best Employer Brand Award, a prestigious recognition presented ...

German multinational pharmaceutical and biotechnology company Bayer is seeking to strengthen its presence in India by expanding its portfolio of therapies and enhancing collaborations across the ...

Bayer Consumer Health has launched a digital educational resource to support perimenopausal or menopausal patients in the UK.

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...